PaxMedica cancels all outstanding shares, deregisters with SEC

PaxMedica, Inc.

Company changed name to Kuvatris Therapeutics; all outstanding shares declared null, void, and worthless.
Shares held by DTC and record shareholders ordered cancelled; beneficial shareholders left with worthless equity.
Company to file Form 15-12g terminating SEC registration, ending all reporting obligations under Exchange Act.
CEO Howard Weisman executed name change on June 6, 2025; share cancellation letter sent to DTC on May 20.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PaxMedica, Inc.: Certificate of amendment changing company name from PaxMedica, Inc. to Kuvatris Therapeutics, Inc (effective 2025-06-06).

Change: charter amendment
Effective: 2025-06-06

Exact text from the filing

On June 6, 2025, Howard J. Weisman, chief executive officer of PaxMedica, Inc., a Delaware corporation (the “Company”), executed a certificate of amendment of the certificate of incorporation of the Company, changing the Company’s name from PaxMedica, Inc. to Kuvatris Therapeutics, Inc.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001641172-25-015067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.